DUBLIN, March 28, 2024 /PRNewswire/ -- The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.
The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities' growth. Again, assistance in using the information is normally provided without additional charges.
After a pandemic interruption the market for Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 120 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Minimal residual disease testing
Emergence of new economies with large markets
Physician diagnostics being displaced by new intelligent diagnostic tests
1.1 Cancer MDx - Strategic Situation Analysis 1.2 Guide for Executives, Marketing, and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 What are Molecular Diagnostics?
2.2 The Diagnostics Revolution
2.3.1 Revenue Market Size
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics
3.1.1 Traditional Market Segmentation
3.1.2 Laboratory Focus and Segmentation
3.2.1 Hospital Testing Share
3.2.3 Physician Office Labs
3.2.4 Physicians and POCT
4.1 Factors Driving Growth
4.1.1 New Diagnostics Create New Markets
4.1.2 New Roles for Diagnostics
4.1.4 Expanding the Pharmaceutical Toolbox
4.2 Factors Limiting Growth
4.2.3 Wellness has a Downside
4.3 Instrumentation, Automation and Diagnostic Trends
4.3.1 Traditional Automation and Centralization
4.3.2 The New Automation, Decentralization and Point Of Care
4.3.3 Instruments Key to Market Share
4.3.4 Bioinformatics Plays a Role
4.3.6 Next Generation Sequencing Fuels a Revolution
4.3.7 NGS Impact on Pricing
4.3.8 Whole Genome Sequencing, A Brave New World
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10 Shifting Role of Diagnostics
4.3.11 Multiplexing and Foundation One
4.3.12 Pharmacogenomics Technology
4.3.13 Gene Editing and Gene Therapy
5 Molecular Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Grail Cancer Test Faces New Clinical Questions 5.6 Digital Pathology Meets Cancer Sequencing 5.7 Exact Sciences Preps Expanded Oncology Portfolio
5.8 Qiagen Details Oncology Plans for Digital PCR Platform 5.9 Sema4 Exiting Reproductive Health Screening
5.10 Thermo Fisher Introduces Cancer Profiling Assay 5.11 Genomic Test IDs Cysts Likely to Progress to Cancer 5.13 Larger Liquid Biopsy Panels Loom
5.15 BillionToOne Raises $125M
5.16 Local Cancer Genomic Profiling Options Grow 5.18 Guardant Health Q3 Revenues Up 27 Percent
5.19 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection 5.21 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics 5.22 Grail Gets Approval for Galleri Multicancer Test
5.23 Finnish Firms to Form Point-of-Care Testing Firm
5.24 Datar Cancer Genetics Expands to Dx and Screening 5.25 HTG Molecular Diagnostics: HTG Transcriptome Panel
5.26 PacBio's Omniome Acquisition Shortens Path to Clinical 5.27 Invitae to Acquire Genosity for $200M
5.28 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test 5.30 Natera Revenues Grow 35 Percent 5.31 AnchorDx Closes $40M Financing Round
5.32 Exact Sciences Strategy for End-to-End Cancer Testing 5.33 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch 6 Profiles of Key MDx Companies
6.4 Adaptive Biotechnologies
6.10 AVIVA Systems Biology
6.11 Baylor Miraca Genetics Laboratories
6.24 bioMerieux Diagnostics
6.27 Bio-Reference Laboratories
6.45 Cytolumina Technologies Corp.
6.76 Integrated Diagnostics
6.84 Menarini Silicon Biosystems
6.94 Novogene Bioinformatics Technology Co., Ltd.
6.97 Ortho Clinical Diagnostics
6.102 Personal Genome Diagnostics
6.116 Siemens Healthineers
For more information about this report visit https://www.researchandmarkets.com/r/le4son
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets